TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00615056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (avastin)
Description: Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Description: Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (avastin)
Description: Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Description: Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT01894269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
Description: In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
Study: NCT02187588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - low dose Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eschscholtzia Californica - high dose Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eschscholtzia Californica - high dose Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen Placebo
Study: NCT01542216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Group
Description: Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga and Stretching Group
Description: Patients randomized to this arm will receive consultations on yoga and stretching exercises.
Study: NCT04645303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 10mg/ml
Description: A1-Pulley infiltration for trigger finger
Study: NCT02936401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
Study: NCT02110316

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage form of voriconazole
Description: Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
Study: NCT04384302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual training
Description: Pre-defined visual training protocol including the optometrical unit exercises
Study: NCT02922270

Intervention type: OTHER
Intervention: Peritoneal dialysis patients at the Istanbul Medical Faculty
Description: The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
Study: NCT05410470

Intervention type: DRUG
Intervention: Ruxolitinib
Study: NCT04130295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable intensive nerve stimulator
Description: The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
Study: NCT02933177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 months control condition - 4 months chariot-flash
Description: The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 months control condition-2 months chariot flash
Description: The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities.
Study: NCT05504629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent training order 1
Description: atag

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT+ET
Description: aetaer
Study: NCT00244712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir
Description: The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Description: The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
Study: NCT00624806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily telephone calls
Description: Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly telephone calls
Description: Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
Study: NCT03639649

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: STHLM3

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STHLM3
Study: NCT02419118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Treatment of myeloma patients with Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment of myeloma patients
Study: NCT02418000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: Single Group Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: Single Group Assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: Single Group Assignment
Study: NCT02090478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet
Description: All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham diet manipulation
Description: Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
Study: NCT03694145

Intervention type: OTHER
Intervention: In-Person Eye Examination
Description: Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
Study: NCT01115205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised walking
Description: Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counselling procedure
Description: Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
Study: NCT03606265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App+Web
Description: Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients will be offered the usual treatment for their pain, which is not changed by study participation
Study: NCT00441168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adriamycin
Description: adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
Study: NCT03938506

Intervention type: OTHER
Intervention: cuff pressure of the endotracheal tube
Description: The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
Study: NCT04016259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrical Stimulation (CES)
Description: CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-CES
Description: For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
Study: NCT03160885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study: NCT01105156

Intervention type: BEHAVIORAL
Intervention: VEW Questionnaire
Description: Patient Self reported questionnaire filled in.
Study: NCT02419118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Treatment of myeloma patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment of myeloma patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treatment of myeloma patients
Study: NCT02578173

Intervention type: DEVICE
Intervention: AVERT PLUS
Study: NCT00644436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: single topical application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tetrix
Description: Single topical application
Study: NCT01232985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD047-26
Description: RD047-26 emollient gel
Study: NCT02915978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl delivered via sublingual spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl delivered via sublingual spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo delivered via sublingual spray
Study: NCT03077204

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
Description: The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.

Intervention type: DEVICE
Group type: OTHER
Intervention: Aviator Anterior Cervical Plating System
Description: The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
Study: NCT01844778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution was administered via nebuliser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistimethate
Description: Colistimethate was administered via nebuliser.
Study: NCT03399474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 2%
Description: Lidocaine Hydrochloride 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 ug/kg
Description: pecedex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection 0.25 ug/kg
Description: pecedex
Study: NCT00964561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Valortim
Description: Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Valortim
Description: Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Placebo Valortim
Description: Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
Study: NCT00614484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
Study: NCT01356654

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Application of Transcranial direct current stimulation (TDCS)
Description: Application of TDCS for 20 minutes, 4 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct current stimulation
Description: Application of true TDCS for 20min, 4 times a week for 4 weeks.
Study: NCT04287738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigated Care
Description: Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
Study: NCT02184221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency stimulation
Description: The parameter of DMS: alpha frequency
Study: NCT02475928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc gluconate
Description: Zinc supplementation plus nutritional education

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00614484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.